Tags

Type your tag names separated by a space and hit enter

Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study.
Radiother Oncol. 2009 Jul; 92(1):83-8.RO

Abstract

BACKGROUND AND PURPOSE

To evaluate the impact of radiotherapy (RT) parameters on outcome in the SIOP/UKCCSG study of pre-RT chemotherapy for Supratentorial Primitive Neuro-ectodermal Tumours.

METHODS AND MATERIALS

Sixty-two patients aged 2.9-16.6 (median 6.4 years) were eligible. Forty-eight (77%) had non-pineal sites and 14 (23%) had pineal sites. Eleven were randomized to RT alone (6) and five to pre-RT Vincristine, Etoposide, Carboplatin and Cyclophosphamide. Fifty-one were not randomized, 15 receiving RT alone and 36 receiving pre-RT chemotherapy. Craniospinal RT (CSRT) 35 Gy/21 fractions were followed by 20 Gy/12 fractions to primary tumour.

RESULTS

Mean CSRT dose was 34.7 Gy and mean total primary dose was 53.4 Gy for those who received radiotherapy. Of 30 relapses, 18 (60%) were local only and 5 (16.7%) were combined local and leptomeningeal. There was no significant impact on Overall Survival (OS) or Event-Free Survival (EFS) of surgery-RT interval for patients treated by pre-RT chemotherapy or RT alone, or duration of RT (completing within 50 days). Planning films were received for 42/54 (77.8%) patients. Fourteen (33%) had one or more targeting deviations (10 cribriform fossa, 11 base of skull). There was a statistically significant increase in the risk of recurrence for patients with cribriform fossa targeting deviations (p=0.033), but not for patients with base of skull targeting deviations (p=0.242). There was no statistically significant difference in OS (p=0.0598) or EFS (p=0.0880) for patients who had one or more targeting deviations compared to those who had none.

CONCLUSIONS

This study has not demonstrated a statistically significant impact of radiotherapy duration or targeting deviations on OS or EFS, possibly due to small patient numbers. However, multi-institutional SPNET trials should incorporate quality assurance programs including analysis of relapse pattern in relation to primary target volume coverage.

Authors+Show Affiliations

Swansea University, Swansea, UK. Roger.Taylor@Swansea-tr.wales.nhs.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19328574

Citation

Taylor, Roger E., et al. "Impact of Radiotherapy Parameters On Outcome for Patients With Supratentorial Primitive Neuro-ectodermal Tumours Entered Into the SIOP/UKCCSG PNET 3 Study." Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, vol. 92, no. 1, 2009, pp. 83-8.
Taylor RE, Donachie PH, Weston CL, et al. Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Radiother Oncol. 2009;92(1):83-8.
Taylor, R. E., Donachie, P. H., Weston, C. L., Robinson, K. J., Lucraft, H., Saran, F., Ellison, D. W., Ironside, J., Walker, D. A., & Pizer, B. L. (2009). Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 92(1), 83-8. https://doi.org/10.1016/j.radonc.2009.02.017
Taylor RE, et al. Impact of Radiotherapy Parameters On Outcome for Patients With Supratentorial Primitive Neuro-ectodermal Tumours Entered Into the SIOP/UKCCSG PNET 3 Study. Radiother Oncol. 2009;92(1):83-8. PubMed PMID: 19328574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. AU - Taylor,Roger E, AU - Donachie,Paul H J, AU - Weston,Claire L, AU - Robinson,Kathryn J, AU - Lucraft,Helen, AU - Saran,Frank, AU - Ellison,David W, AU - Ironside,James, AU - Walker,David A, AU - Pizer,Barry L, AU - ,, Y1 - 2009/03/26/ PY - 2008/05/30/received PY - 2009/02/16/revised PY - 2009/02/26/accepted PY - 2009/3/31/entrez PY - 2009/3/31/pubmed PY - 2009/10/29/medline SP - 83 EP - 8 JF - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology JO - Radiother Oncol VL - 92 IS - 1 N2 - BACKGROUND AND PURPOSE: To evaluate the impact of radiotherapy (RT) parameters on outcome in the SIOP/UKCCSG study of pre-RT chemotherapy for Supratentorial Primitive Neuro-ectodermal Tumours. METHODS AND MATERIALS: Sixty-two patients aged 2.9-16.6 (median 6.4 years) were eligible. Forty-eight (77%) had non-pineal sites and 14 (23%) had pineal sites. Eleven were randomized to RT alone (6) and five to pre-RT Vincristine, Etoposide, Carboplatin and Cyclophosphamide. Fifty-one were not randomized, 15 receiving RT alone and 36 receiving pre-RT chemotherapy. Craniospinal RT (CSRT) 35 Gy/21 fractions were followed by 20 Gy/12 fractions to primary tumour. RESULTS: Mean CSRT dose was 34.7 Gy and mean total primary dose was 53.4 Gy for those who received radiotherapy. Of 30 relapses, 18 (60%) were local only and 5 (16.7%) were combined local and leptomeningeal. There was no significant impact on Overall Survival (OS) or Event-Free Survival (EFS) of surgery-RT interval for patients treated by pre-RT chemotherapy or RT alone, or duration of RT (completing within 50 days). Planning films were received for 42/54 (77.8%) patients. Fourteen (33%) had one or more targeting deviations (10 cribriform fossa, 11 base of skull). There was a statistically significant increase in the risk of recurrence for patients with cribriform fossa targeting deviations (p=0.033), but not for patients with base of skull targeting deviations (p=0.242). There was no statistically significant difference in OS (p=0.0598) or EFS (p=0.0880) for patients who had one or more targeting deviations compared to those who had none. CONCLUSIONS: This study has not demonstrated a statistically significant impact of radiotherapy duration or targeting deviations on OS or EFS, possibly due to small patient numbers. However, multi-institutional SPNET trials should incorporate quality assurance programs including analysis of relapse pattern in relation to primary target volume coverage. SN - 1879-0887 UR - https://www.unboundmedicine.com/medline/citation/19328574/Impact_of_radiotherapy_parameters_on_outcome_for_patients_with_supratentorial_primitive_neuro_ectodermal_tumours_entered_into_the_SIOP/UKCCSG_PNET_3_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-8140(09)00084-X DB - PRIME DP - Unbound Medicine ER -